Truist lowered the firm’s price target on Edwards Lifesciences to $76 from $83 but keeps a Buy rating on the shares. The company posted an in-line Q3, with TAVR growth continuing its double-digit growth streak, even though an incremental FX headwind will keep its revenue and earnings towards the lower-end of the reiterated FY23 guidance ranges, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target lowered to $80 from $100 at TD Cowen
- Edwards Lifesciences price target lowered to $68 from $83 at Piper Sandler
- Edwards Lifesciences price target lowered to $84 from $100 at JPMorgan
- Edwards Lifesciences price target lowered to $75 from $91 at Baird
- Edwards Lifesciences price target lowered to $85 from $90 at Mizuho
